Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
PTC Therapeutics, Inc is a biotechnology business based in the US. PTC Therapeutics shares (PTCT) are listed on the NASDAQ and all prices are listed in US Dollars. PTC Therapeutics employs 754 staff and has a trailing 12-month revenue of around USD$358.4 million.
|Latest market close||USD$61.2|
|52-week range||USD$30.7923 - USD$64.62|
|50-day moving average||USD$57.738|
|200-day moving average||USD$51.8221|
|Wall St. target price||USD$61.58|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.1|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||N/A|
|1 month (2020-11-06)||3.07%|
|3 months (2020-09-02)||N/A|
|6 months (2020-06-02)||N/A|
|1 year (2019-12-02)||N/A|
|2 years (2018-12-02)||N/A|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
Valuing PTC Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PTC Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PTC Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.81. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PTC Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$358.4 million|
|Gross profit TTM||USD$37.4 million|
|Return on assets TTM||-10.26%|
|Return on equity TTM||-75.17%|
|Market capitalisation||USD$4.4 billion|
TTM: trailing 12 months
There are currently 4.7 million PTC Therapeutics shares held short by investors – that's known as PTC Therapeutics's "short interest". This figure is 3.8% up from 4.5 million last month.
There are a few different ways that this level of interest in shorting PTC Therapeutics shares can be evaluated.
PTC Therapeutics's "short interest ratio" (SIR) is the quantity of PTC Therapeutics shares currently shorted divided by the average quantity of PTC Therapeutics shares traded daily (recently around 436328.86405959). PTC Therapeutics's SIR currently stands at 10.74. In other words for every 100,000 PTC Therapeutics shares traded daily on the market, roughly 10740 shares are currently held short.
However PTC Therapeutics's short interest can also be evaluated against the total number of PTC Therapeutics shares, or, against the total number of tradable PTC Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PTC Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 PTC Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0704% of the tradable shares (for every 100,000 tradable PTC Therapeutics shares, roughly 70 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against PTC Therapeutics.
Find out more about how you can short PTC Therapeutics stock.
We're not expecting PTC Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, PTC Therapeutics's shares have ranged in value from as little as $30.7923 up to $64.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PTC Therapeutics's is 1.1838. This would suggest that PTC Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.